Diagonal Therapeutics
Diagonal Therapeutics Raises $125M Series B | Antibody Therapeutics
Diagonal Therapeutics Closes $125M Series B
Diagonal Therapeutics, developing disease-modifying clustering antibodies for rare genetic diseases, has raised $125 million in Series B funding.
The round was led by Sanofi Ventures and Janus Henderson Investors.
Key Highlights
- Focus on rare genetic diseases
- Novel antibody platform
- Strategic pharma backing from Sanofi
Company Overview
Diagonal Therapeutics is pioneering a new class of therapeutics using clustering antibodies to address rare genetic diseases with high unmet medical need.
Company Info
Investors (2)
Share
Related Reports
Wabi Raises $55M at $1.25B Valuation in IVP-Led Funding
Wabi announced $55 million in funding led by IVP at a $1.25 billion valuation, which it said will support continued product development and expansion.
StimCardio Raises $30M Series A for Wearable AF Therapeutic
StimCardio announced the closing of an oversubscribed $30 million Series A led by Metis Medtech, expected to fund the company through its planned NeuroPulse 2 pivotal study and preparation for an FDA De Novo submission.
Casap Raises $56M Series B for AI Agents in Financial Services
Casap raised a $56 million Series B led by Base10 Partners, with Experian and Synchrony participating, to advance its AI agent platform for financial services.
Turn your sales ideas into reality today
Pick a plan and go live today. Change or cancel any time.
Get started